327 reports of this reaction
2.3% of all DAPTOMYCIN reports
#8 most reported adverse reaction
BLOOD CREATINE PHOSPHOKINASE INCREASED is the #8 most commonly reported adverse reaction for DAPTOMYCIN, manufactured by APOTEX CORP.. There are 327 FDA adverse event reports linking DAPTOMYCIN to BLOOD CREATINE PHOSPHOKINASE INCREASED. This represents approximately 2.3% of all 14,068 adverse event reports for this drug.
Patients taking DAPTOMYCIN who experience blood creatine phosphokinase increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD CREATINE PHOSPHOKINASE INCREASED is a less commonly reported adverse event for DAPTOMYCIN, but still significant enough to appear in the safety profile.
In addition to blood creatine phosphokinase increased, the following adverse reactions have been reported for DAPTOMYCIN:
The following drugs have also been linked to blood creatine phosphokinase increased in FDA adverse event reports:
BLOOD CREATINE PHOSPHOKINASE INCREASED has been reported as an adverse event in 327 FDA reports for DAPTOMYCIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD CREATINE PHOSPHOKINASE INCREASED accounts for approximately 2.3% of all adverse event reports for DAPTOMYCIN, making it a notable side effect.
If you experience blood creatine phosphokinase increased while taking DAPTOMYCIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.